No profile data available.
Karyopharm Therapeutics Inc. (KPTI) is a healthcare company in the blood cancer treatment drugs industry, based in Newton, United States, with about 228 full-time employees.
It reported revenue of $146.07 million for fiscal year 2025, up 0.6% from fiscal year 2024, and net income of -$196.04 million. Its market capitalization was $13.72 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States.
Karyopharm Therapeutics reported $146.07 million in revenue for fiscal year 2025, up 0.6% from $145.24 million in fiscal year 2024.
$13.72 million as of October 9, 2026.
Listed companies of a similar size in the same industry (blood cancer treatment drugs) include Actinium Pharmaceuticals, Inc. (ATNM), Estrella Immunopharma, Inc. (ESLA), Marker Therapeutics, Inc. (MRKR), Cellectar Biosciences, Inc. (CLRB).